FHTX

Foghorn Therapeutics Inc. (FHTX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Foghorn Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is currently advancing one clinical-stage drug candidate, FHD-909, in collaboration with Eli Lilly and Company ("Lilly"). Foghorn operates as a single segment and is classified as a smaller reporting company and an emerging growth company.

Key Financial Metrics

Note: Cash, cash equivalents, and marketable securities as of June 30, 2025, totaled $198.7 million ($72.6M cash + $126.1M marketable securities).

Material Changes vs. Prior Period

• Revenue Growth: Collaboration revenue increased by 10% year-over-year for the quarter and 13% year-over-year for the six-month period, driven by continued advancement of programs under the Lilly Collaboration Agreement.
• Expense Reduction: Total operating expenses decreased by 15% in Q2 and 14% YTD compared to the prior year. This was primarily due to:
  • FHD-286 Discontinuation: A significant reduction in costs ($2.5M in Q2, $5.0M YTD) following the decision in December 2024 to discontinue the independent development of FHD-286.
  • Lower External Costs: Decreases in preclinical research costs and early development expenses.
• Increased Partnered Spend: Expenses for Lilly partnered programs increased by $1.8M in Q2 and $2.6M YTD, driven by the initiation of the Phase 1 dose escalation study for FHD-909.
• Impairment Charges: The prior year included a $2.4M non-cash impairment charge related to subleased office space; no such charge was recorded in 2025.
• Lease Restructuring: In June 2025, the company entered a new lease in Watertown, MA, and amended its Cambridge lease, resulting in an $8.8M reduction to the right-of-use asset and lease liability.

Outlook, Risks, and Management Commentary

• Liquidity: Management expects cash, cash equivalents, and marketable securities to be sufficient to fund operations for at least 12 months from the filing date. No new equity financing was raised in the current period.
• Pipeline Updates:
  • FHD-909: Phase 1 dose escalation study dosed its first patient in October 2024. Costs are shared 50/50 with Lilly.
  • FHD-286: Independent development discontinued; Phase 1 trial winding down.
• Deferred Revenue: As of June 30, 2025, $266.6 million of deferred revenue remains related to the Lilly Collaboration Agreement, expected to be recognized through 2029 or beyond.
• Risks: The company faces standard biotech risks including the need for additional capital, clinical trial uncertainties, and reliance on the Lilly collaboration. Geopolitical instability and inflation are cited as potential cost drivers.
• Forward-Looking Statements: The filing contains predictions regarding clinical timelines, regulatory approvals, and capital needs, which are subject to significant uncertainty.

Investor Verification Checklist

• Cash Runway: Verify the 12-month liquidity estimate against current burn rates, considering the increased spend on the FHD-909 Phase 1 trial.
• Revenue Recognition: Review the "cost-to-cost" method used for recognizing the $300M Lilly upfront payment to understand volatility in future revenue reporting.
• Lease Obligations: Confirm the impact of the new Watertown lease and the amended Cambridge lease on future cash flow commitments.
• Program Status: Monitor enrollment and safety data for the FHD-909 Phase 1 trial, as this is the primary driver of future value and cost-sharing obligations.
• Capital Needs: Assess the likelihood and timing of future equity dilution or debt financing required to sustain operations beyond the 12-month horizon.